MINI FUTURE LONG - MODERNA | Market Closed - Börse Stuttgart 20:51:01 05/07/2024 BST | ||
| 5.79 EUR | +0.17% |
|
| Current month | -1.70% | ||
| 1 month | -36.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 5.79 | +0.17% |
| 04/07/24 | 5.78 | +3.96% |
| 03/07/24 | 5.56 | -2.46% |
| 02/07/24 | 5.7 | +1.06% |
| 01/07/24 | 5.64 | -4.24% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 08:51 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Morgan Stanley |
| WKN | MB9ARU |
| ISIN | DE000MB9ARU5 |
| Date issued | 31/07/2023 |
| Strike | 55.79 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.47 € |
|---|---|
| Lowest since issue | 1.29 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3
USD
Average target price
145.9
USD
Spread / Average Target
+23.27%
- Stock Market
- Certificates
- Certificat
